Thermo Fisher Scientific, Bloom Energy, Danaher, Icon, IQVIA, Abivax, and AbbVie are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies whose primary business involves using biological science and technology to develop products such as drugs, vaccines, diagnostics and biofuels. Because these firms often rely on lengthy and costly research and regulatory approvals before generating revenue, their stock prices can be especially volatile. Investors in biotech stocks typically seek high growth potential while accepting greater risk compared to more established industries. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of Thermo Fisher Scientific stock traded up $16.20 during trading hours on Thursday, hitting $482.91. The company's stock had a trading volume of 3,049,614 shares, compared to its average volume of 2,475,703. Thermo Fisher Scientific has a 12 month low of $385.46 and a 12 month high of $627.88. The stock has a 50 day moving average of $411.01 and a 200 day moving average of $471.10. The company has a market capitalization of $182.30 billion, a PE ratio of 28.31, a price-to-earnings-growth ratio of 2.06 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38.
Read Our Latest Research Report on TMO
Bloom Energy (BE)
Bloom Energy Corporation designs, manufactures, sells, and installs solid-oxide fuel cell systems for on-site power generation in the United States and internationally. The company offers Bloom Energy Server, a solid oxide technology that converts fuel, such as natural gas, biogas, hydrogen, or a blend of these fuels into electricity through an electrochemical process without combustion.
BE stock traded up $6.08 during mid-day trading on Thursday, reaching $32.97. The company had a trading volume of 24,261,248 shares, compared to its average volume of 6,586,152. The company has a market capitalization of $7.66 billion, a price-to-earnings ratio of -659.27 and a beta of 3.22. The company has a debt-to-equity ratio of 2.07, a current ratio of 3.44 and a quick ratio of 2.39. The stock has a 50 day simple moving average of $22.23 and a two-hundred day simple moving average of $21.91. Bloom Energy has a 52 week low of $9.02 and a 52 week high of $33.33.
Read Our Latest Research Report on BE
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Shares of Danaher stock traded up $5.37 on Thursday, hitting $203.26. The company had a trading volume of 3,660,170 shares, compared to its average volume of 4,236,911. The stock has a 50 day moving average of $195.94 and a 200-day moving average of $204.39. Danaher has a 1 year low of $171.00 and a 1 year high of $281.70. The stock has a market capitalization of $145.46 billion, a price-to-earnings ratio of 43.29, a P/E/G ratio of 2.65 and a beta of 0.77. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43.
Read Our Latest Research Report on DHR
Icon (ICLR)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
NASDAQ:ICLR traded up $30.19 during trading hours on Thursday, hitting $198.08. 2,685,782 shares of the company's stock traded hands, compared to its average volume of 1,312,488. The business's fifty day simple moving average is $141.46 and its two-hundred day simple moving average is $164.54. The company has a quick ratio of 1.27, a current ratio of 1.27 and a debt-to-equity ratio of 0.36. The firm has a market cap of $16.00 billion, a P/E ratio of 21.26, a P/E/G ratio of 2.43 and a beta of 1.17. Icon has a 52 week low of $125.10 and a 52 week high of $338.67.
Read Our Latest Research Report on ICLR
IQVIA (IQV)
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Shares of IQV stock traded up $8.70 during trading hours on Thursday, reaching $202.94. 2,322,026 shares of the company traded hands, compared to its average volume of 2,019,616. IQVIA has a 12-month low of $134.65 and a 12-month high of $252.88. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.82. The company has a market cap of $35.11 billion, a P/E ratio of 29.33, a P/E/G ratio of 2.21 and a beta of 1.30. The firm has a 50-day moving average price of $154.75 and a 200 day moving average price of $170.52.
Read Our Latest Research Report on IQV
Abivax (ABVX)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Shares of Abivax stock traded up $1.06 on Thursday, hitting $69.66. 5,821,570 shares of the company traded hands, compared to its average volume of 533,090. The stock's 50 day moving average price is $8.55 and its 200-day moving average price is $7.26. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.25 and a current ratio of 1.25. Abivax has a 52 week low of $4.77 and a 52 week high of $72.90.
Read Our Latest Research Report on ABVX
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of AbbVie stock traded up $0.36 during trading hours on Thursday, reaching $190.91. The stock had a trading volume of 1,188,934 shares, compared to its average volume of 6,885,706. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14. The firm has a market capitalization of $337.22 billion, a PE ratio of 81.29, a PEG ratio of 1.24 and a beta of 0.48. The stock's 50 day moving average is $187.31 and its 200 day moving average is $189.55. AbbVie has a twelve month low of $163.81 and a twelve month high of $218.66.
Read Our Latest Research Report on ABBV
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
